Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Huntington Ingalls Industries Inc (HII) vs Smith & Nephew plc (SNN) Price & Performance

Huntington Ingalls Industries IncTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Huntington Ingalls Industries Inc vs Smith & Nephew plc — how do they compare? Huntington Ingalls Industries Inc trades at $326 (market cap $12.92B), while Smith & Nephew plc trades at $30.05 (market cap $12.54B). The key difference: Huntington Ingalls Industries Inc and Smith & Nephew plc are close in size by market cap, and Smith & Nephew plc pays the higher dividend (2.65%). Which is the better fit depends on your goals.

HIISNN
Market Cap
$12.92B$12.54B
Sector
TechnologyHealth
52-Week High
$453.73$38.70
52-Week Low
$265.40$28.73
Enterprise Value
$15.84B$15.57B
Dividend Yield
1.68%2.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Huntington Ingalls Industries Inc

HII trades at $326.80, down 1.21% over the past day, with a bullish technical outlook supported by moving averages and key support at $326. The company reported strong Q2 2026 earnings of $5.27 EPS, beating estimates, with revenue growth of 10.9% year-over-year. Recent contract awards, including a $2.2 billion task order for surveillance and intelligence capabilities, highlight ongoing government demand. Valuation metrics show a P/E of 19.53 and P/S of 0.98, indicating reasonable pricing relative to earnings and sales.

The investment outlook is positive, driven by robust defense contracts and operational improvements, with a consensus price target of $359.67 suggesting 10% upside. Risks include dependence on U.S. military spending and potential political headwinds affecting naval budgets. Analyst sentiment is mixed but leans bullish, with 44% buy ratings. Overall, HII presents a solid opportunity in the defense sector, though investors should monitor contract execution and macroeconomic factors.

Smith & Nephew plc

SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.

The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Huntington Ingalls Industries Inc

Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.

Read more on HII

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN